On this page
Key dates
-
Abstract Submissions Open
21 August 2024 -
Early Bird Registrations
February to May 2025 -
Abstract Submissions Close
28 March 2025 -
Abstract Acceptance Notification
June 2025 -
Standard Registrations
May to August 2025 -
Late Registrations
August to September 2025 -
APLAR 2025 Congress
3-7 September 2025
Further questions
If you have any questions regarding abstract submissions, the program or the congress as a whole, please contact the APLAR Program Manager.
Abstract submissions for the 27th Asia-Pacific League of Associations for Rheumatology congress are now open. All details you need to submit your work are outlined on this page – ensure you have your chance to present your work at APLAR 2025 and submit before the deadline.
Before submitting your abstract, ensure you read the below guidelines carefully. All the information that you require is included below.
Important note: Please ensure that you add “wearemci.com” and “aplarcongress.com” to your white list / accepted email lists. This will ensure that you receive all necessary communications from us regarding your congress participation.
Abstract presentation guidelines
We have prepared abstract guidelines to assist you with preparing your abstract for the congress.
It is important to read these carefully when preparing for your submission.
To read detailed information below please click on “+” buttons below.
Abstract submission guidelines
Outlined below are the guidelines that must be followed when submitting your work to APLAR 2025.
- All submissions must be in English. English is the official congress language and all presentations must also be in English
- Submission titles must not be longer than 20 words and must clearly indicate the nature of the presentation
- Submissions must not exceed 400 words, be clear and concise, highlight relevant aspects, findings and conclusions
- Only standard abbreviations may be used within submissions
- References are not required for submissions
- The abstract title, section headings and references are not included in the overall word count
- Abstracts should follow the following format
- Background/Purpose: background or statement of purpose
- Methods: methods, materials and analytical procedure used
- Results: summary of the results in sufficient detail to support conclusion (we do not recommend including “results will be discussed”)
- Conclusion: conclusions reached
- Tables, graphs and images are permitted within submissions (maximum 2)
- What is an encore presentation?
An encore presentation is one where you have already presented the submitted work before. For example if you have presented the work at another rheumatology event. - Does APLAR 2025 accept encore presentations?
- Yes we do accept encore presentations
- Encore presentations are permitted as long as work has been presented after APLAR 2024 (21 – 25 August 2024)
- Encore presentations are permitted as long as work has not previously been published prior to submission
- Encore submissions are required to disclose the name and date of the event where it has been presented
- Original abstracts are strongly recommended
IMPORTANT
Please enter submission information carefully, information will be published exactly as submitted
All abstract submissions must be received online through the abstract submission portal.
Abstract submission topics
- Advances in pain management
- Allied health: alternative medicine
- Allied health: case report
- Allied health: COVID-19
- Allied health: nursing
- Allied health: physiotherapy
- Allied health: psychological intervention and miscellaneous forms of care
- Antiphospholipid syndrome
- Autoinflammatory diseases
- Basic science related to rheumatic diseases
- Behcet’s disease and miscellaneous rheumatic conditions
- Big data
- Case report
- Clinical immunology related to rheumatic diseases
- COVID-19
- Crystal-induced diseases
- Epidemiology, COPCORD, health care system and pharmacoeconomics
- Fibromyalgia
- Genetics
- IgG4-related disease
- Imaging techniques and diagnosis
- Infection-related rheumatic diseases
- Medical technologies and innovation (including AI)
- Metabolic bone diseases
- Osteoarthritis
- Paediatric rheumatology
- Precision medicine
- Psoriatic arthritis
- Rehabilitation for rheumatic diseases
- Rheumatoid arthritis anti-TNF therapy
- Rheumatoid arthritis bDMARDs
- Rheumatoid arthritis clinical aspects and co-morbidity
- Rheumatoid arthritis csDMARDs
- Rheumatoid arthritis non biological treatment
- Rheumatoid arthritis non-TNF biological therapies
- Rheumatoid arthritis tsDMARDs
- Scleroderma, myositis and related syndromes
- Sjogren syndrome
- Soft tissue rheumatism
- Spondylarthropathies biological and non-biological therapies
- Spondylarthropathies clinical aspects and co-morbidity
- Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications
- Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies
- Systemic vasculitis related to rheumatic diseases
- Telemedicine
Presentation formats
Abstracts can be submitted for either oral or poster presentations.
Oral presentations
Oral presentations will be asked to present an oral presentation at the congress including a PowerPoint presentation and Q&A with the audience.
Poster presentations
Poster presentations will be asked to present a traditional physical poster display.
Abstract review
- All submitted abstracts will be peer reviewed (blind review) by a subsection of the APLAR 2025 Scientific Committee
- Incomplete abstracts or abstracts not written in English cannot be processed and will not be reviewed
- No revisions are possible after the submission deadline – no exceptions.
Conditions of acceptance
If accepted into the official program; the following conditions will apply:
- Oral presentations can only be presented by one author
- Presenters must be a listed author on the submission
- Accepted presenters must register, pay and attend the congress (in-person), otherwise the abstract will not be included in the official program or published in the IJRD supplement
- Abstract submissions remain the property of APLAR and the Scientific Committee reserves the right to publish and distribute
Terms and conditions
All abstract submitters are required to agree to the below terms and conditions prior to submitting their work:
- Submitting author hereby commits with the present data protection and privacy policy
- Submitting authors declare that the submission is the original work of at least one author/presenter
- No funding is provided to accepted presenters. Accepted presenters acknowledge they must register, pay and attend the congress for their work to be included in the official program.
- Submitting authors must declare the work described in the abstract has appropriate approval under local, ethical and animal experimentation rules
- Submitting authors must declare that their work does not conflict with any existing copyright agreements with alternate publishers
- Submitting authors provide consent for their presentation materials to be used to assist APLAR 2025, future congresses and on-demand content
